Inhibition of NGLY1 for the treatment of cancer

US11779592B2 · kind B2 · utility

Assignee

• UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER · US

Inventors

• Yu Wang · San Jose, US
• Victor J. T. Lin · Fort Worth, US
• Ashwini Zolekar · Fort Worth, US
• Kyle A. Emmitte · Durham, US
• Nigam M. Mishra · Fort Worth, US
• Jin Liu · Beijing, CN

Key dates

• Filing date: Aug 14, 2018
• Grant date: Oct 10, 2023
• Expiry date: Jul 15, 2039

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12Y305/01052
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

In one aspect, the present disclosure provides GlcNAc-Asn analogs of the formula (I): wherein the variables are as defined herein. In another aspect, the present disclosure also provides pharmaceutical compositions and methods of using the compounds disclosed herein. Additionally, the present disclosure also provides methods of treating cancer comprising inhibiting NGLY1.